Clinical trial
Safety and Efficacy of Aliskiren in Post Myocardial Infarction Patients (ASPIRE)
NCT00414609 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00414609 |
|---|---|
| Title | Safety and Efficacy of Aliskiren in Post Myocardial Infarction Patients (ASPIRE) |
| Official title | A 36-week, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Including a 2 Year Extension Study to Evaluate Efficacy and Safety of Aliskiren on the Prevention of Left Ventricular Remodeling in High Risk Post-acute Myocardial Infarction Patients When Added to Optimized… |
| Lead sponsor | Novartis, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Myocardial Infarction |
| Intervention type | Drug |
| Interventions | Aliskiren, placebo |
| Enrollment | 820 |
| Start date | Dec 1, 2006 |
| Primary completion | Sep 1, 2009 |
| Completion | Jul 1, 2011 |
| First posted | Dec 21, 2006 |
| Last update posted | Jul 13, 2012 |
| Countries | Argentina, Belgium, Canada, Colombia, Czechia, Denmark, Germany, Hungary, India, Israel, Italy, Netherlands and 11 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: